Stimunity is a preclinical-stage startup company which develops best-in-class drugs on the STING pathway to activate the innate immune system. Stimunity drugs stimulate patients immune system to fight back infectious pathogens or cancer.
Stimuntiy is hosted by Institut Curie and incubated by Paris Biotech Sant_ and technology is based on academic research work from: Institut Curie, the French National Institute of Health and Medical Research (Inserm) and University of Oxford.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/stimunity” connections=”true” suffix=””]
Stimunity focuses on the STING pathway, which is known to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells. By addressing this target with a unique biologic approach which combines the the endogenous STING activator encapsulated in a Virus-Like Particle (VLP), Stimunitys drugs are best-in-class.
In Feb 2018, Stimunity received 2M seed funding from Portage, a US/Canadian listed company actively investing in promising
companies that have the potential to be a game changer in the immunotherapy field. Earlier in June 2016, Stimunity received a non-dilutive financing of 60k from Scientip_le Initiative to complete the proof-of-concept package.
Recover your password.
A password will be e-mailed to you.